A New Steroid That Quickly Helps With Depression

Women are <a href="https://www.sciencedirect.com/science/article/abs/pii/S0031938409000808?via%3Dihub=" rel="noopener ugc nofollow" target="_blank">twice as likely </a>as men to become depressed. Depression is most likely to strike women at the end of pregnancy, what we call postpartum depression. (PPD). PPD is more common than any other<a href="https://www.marchofdimes.org/find-support/topics/postpartum/postpartum-depression#:~:text=PPD%20is%20the%20most%20common,symptoms%20of%20depression%20during%20pregnancy." rel="noopener ugc nofollow" target="_blank"> medical complication</a> after delivering a baby, occurring in as many as 17% of new mothers. But despite the frequency of occurrence, and improvements in screening and detecting PPD, the majority of cases go untreated. Two years ago, brexanolone, a steroid with biological actions in the brain, was approved for treating PPD. But<a href="https://www.ncbi.nlm.nih.gov/books/NBK541054/#:~:text=Brexanolone%20is%20administered%20as%20a,to%2060%20mcg%2Fkg%2Fhour" rel="noopener ugc nofollow" target="_blank"> brexanolone</a> requires a clinic or hospital visit for a 60-hour continuous IV infusion, and carries a $34,000 price tag. In contrast, zuranolone (sold under the brand name Zurzuvae), approved in August by the FDA, is a daily pill, and is expected to be available to patients before the end of the year. <a href="https://medium.com/wise-well/a-new-steroid-that-quickly-helps-with-depression-efd8841b4012">Visit Now</a>